about
Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal.Towards control of the global HIV epidemic: Addressing the middle-90 challenge in the UNAIDS 90-90-90 targetVirological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.Older HIV-infected individuals present late and have a higher mortality: Brighton, UK cohort study.Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised TrialAccess to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP cluster-randomized trial in rural South AfricaAntiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa.The Art of HIV Elimination: Past and Present Science."It is better to die": experiences of traditional health practitioners within the HIV treatment as prevention trial communities in rural South Africa (ANRS 12249 TasP trial).Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa.Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria.Morbidity in HIV-1-infected individuals before and after the introduction of antiretroviral therapy: a longitudinal study of a population-based cohort in Uganda.Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa.Community perceptions of repeat HIV-testing: experiences of the ANRS 12249 Treatment as Prevention trial in rural South Africa.HIV treatment as prevention: applicable in sub-Saharan Africa?HIV testing: the 'front door' to the UNAIDS 90-90-90 target.Reply to Cohen et al.Universal test and treat is not associated with sub-optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial.Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for aHIV Ascertainment through Repeat Home-based Testing in the Context of a Treatment as Prevention Trial (ANRS 12249 TasP) in Rural South AfricaImpact of next generation sequencing defined HIV pre-treatment drug resistance on virological outcomes in the ANRS 12249 treatment as prevention trialNephrotic Syndrome in LeishmaniasisWhat do the Universal Test and Treat trials tell us about the path to HIV epidemic control?Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South AfricaClinical outcomes after first-line HIV treatment failure in South Africa: the next cascade of care
P50
Q30625366-E98CE0FC-E931-48D4-86A7-7CA674B1D287Q33626363-B95214E9-4478-4C41-97F8-7C3B288C3353Q33712438-E06663B4-CB8A-4357-A83C-193F825F3BA9Q34691316-1B1A87B0-B244-4F59-9ABB-4FB09D3B924BQ36098544-FF3A148C-434E-43E5-A1E6-D856456C8F11Q36965839-2F518F8A-7D6F-42CB-A130-BD6B6FBD9C74Q37140535-F2F59277-A7BA-42C7-920A-306DE9A2A2C0Q37354106-E094A1DA-AA97-466F-B15D-9956077B04C8Q37395464-08E507FF-6EB5-4146-B68B-AE8710495E8AQ37395475-2DB96DE7-C06F-4E30-B914-2798914B683EQ37401923-1F4918C7-27BD-4EB5-9CB8-FAFE28552D59Q38870300-57D5306F-1B8A-4717-850F-1C09B09FF57BQ39209322-9E0CC2FC-5257-4C54-A0DA-71C85E4C0161Q40612148-5699449B-4FCF-4829-B6A8-11EA9F37A129Q40676385-64A6069D-0935-4D88-ADB3-6E7F04AAB3F3Q42333103-9824B7F0-621F-48E2-8DFE-0B04E6164A2DQ44007686-CA0A81D8-D62A-4280-BFE6-1DAFAC2613B0Q55272863-F76DDA72-EE37-40E9-8C65-E6BD9E8AAC8EQ55546871-45F85664-6C6E-48DC-8441-F9852FD17F37Q56833624-D016C776-3DC1-4771-9DDB-16A498C4F815Q57461945-5864FE01-287B-4647-ADDC-E0B2592A4CCCQ58205697-2A4006E2-2157-40DA-B3E3-28335B39E09CQ89854005-2EA58D85-ED27-41D2-98BE-1DAB9DF5818CQ90866855-7A4382C2-B3AD-45E7-900C-C2647B8F4FFFQ96113042-F8C2F3DF-B114-48DE-BF16-6AD6942AC17F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Collins C Iwuji
@ast
Collins C Iwuji
@en
Collins C Iwuji
@es
Collins C Iwuji
@nl
type
label
Collins C Iwuji
@ast
Collins C Iwuji
@en
Collins C Iwuji
@es
Collins C Iwuji
@nl
prefLabel
Collins C Iwuji
@ast
Collins C Iwuji
@en
Collins C Iwuji
@es
Collins C Iwuji
@nl
P108
P106
P108
P1153
25641410300
P214
4733151656280808400003
P31
P496
0000-0003-2045-1717
P7859
viaf-4733151656280808400003